アビンサイエンス｜組換えタンパク質、抗体及びアッセイキット

Semaglutide vs. Tirzepatide vs. Retatrutide: A Researcher's Guide to Incretin Drug Detection and Analysis

This guide compares semaglutide, tirzepatide, and retatrutide from a research reagent perspective — covering PK ELISA kits, ADA immunogenicity assays, receptor antibodies, and biosimilar reference standards for preclinical and translational studies.

詳細を見る

p16INK4a (CDKN2A) Antibodies & Nanobodies — Senescence & Tumor Suppressor Research

Anti-p16INK4a/CDKN2A antibodies, VHH nanobodies, and recombinant proteins from abinScience. Polyclonal antibodies for human and mouse, nanobody SAA2259 for enhanced IHC tissue penetration, plus His-tagged and GST-tagged p16 proteins for assay controls and CDK inhibition studies.

詳細を見る

From GLP-1 to the Multi-Target Era: ADA 2026 Unveils New Directions in Weight-Loss Drug R&D

ADA 2026 highlights the shift from single-target GLP-1RAs to multi-target agonists (dual/triple), oral small molecules, and ultra-long-acting injectables. The latest triple-agonist data (LY3437943) show >30% weight loss, while biased oral agonists improve tolerability. Multi-target synergy, oral convenience, and neuroimaging deepen efficacy and mechanistic understanding.

詳細を見る

WHO Reports a Cruise Ship Hantavirus Cluster: A Multidimensional Analysis of Pathogen Biology and Pathogenesis

In May 2026, WHO reported a cruise ship cluster of fatal Hantavirus Pulmonary Syndrome (HPS) cases caused by Andes virus (ANDV), This article provides a multidimensional analysis of hantavirus, covering pathogenic characteristics (genome organization into L, M, S segments), transmission routes, molecular mechanisms of vascular endothelial dysfunction, cytokine storm, and clinical syndromes (HFRS and HPS).

詳細を見る

Kent Meningococcal Outbreak 2026: Invasive MenB Disease Mechanisms and Vaccine Breakthroughs

Latest update on the 2026 Kent, UK MenB meningitis outbreak (27 cases, 2 deaths). In-depth look at Neisseria meningitidis pathogenesis, intracellular escape, blood-brain barrier crossing, key antigens (FHbp, NHBA, NadA), and 2025–2026 pentavalent MenABCWY vaccine advances (PENBRAYA, PENMENVY).

詳細を見る

Biosimilars Enter a New Growth Phase: Biologics R&D Trends and Research Opportunities in 2026

Biosimilars are entering a new deterministic growth cycle in 2026, fueled by the intensive patent expiration of global blockbuster biologics and the continuous improvement of worldwide regulatory systems. This article outlines core 2026 biologics R&D trends, identifies autoimmune diseases as the key R&D track, details four core immune regulatory pathways and blockbuster candidates expected to be approved in 2026, and elaborates the industrial, clinical and research value of biosimilar

詳細を見る

2025 Update on Systemic Lupus Erythematosus (SLE): Core Pathogenic Targets, Emerging Biologics, and CAR-T Therapy Advances

This comprehensive review explores the latest insights into systemic lupus erythematosus (SLE) pathogenesis as of early 2026, focusing on key targets such as IFN-I signaling, BAFF/APRIL pathways, and CD19/CD20 on B cells. It highlights recent clinical advances, including expanded real-world efficacy of anifrolumab and telitacicept, promising results from CD19-targeted CAR-T therapies achieving deep remission in refractory cases, and emerging multi-target biologics. The article also recommends high-specificity research tools for mechanistic studies and drug development.

詳細を見る

2026–2027 Influenza Research Targets Updated: WHO Announces Recommended Vaccine Strains for the Northern Hemisphere

WHO released the 2026–2027 northern hemisphere influenza vaccine composition, emphasizing updated strains for H1N1, H3N2, and B/Victoria lineages. The announcement highlights rapid viral evolution, zoonotic risks, and priority research directions including H9N2 preparedness, supporting global influenza research and vaccine development.

詳細を見る

Unpacking House Dust Mite Pathogenic Mechanisms: From Allergen Proteins to Immunotherapeutic Advances

House Dust Mite Allergy (HDMA), a prevalent IgE-mediated Type I hypersensitivity, is primarily triggered by allergens from Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f). This review comprehensively explores the ecological and biological characteristics of dust mites, the pathogenic mechanisms involving epithelial barrier disruption and Th2-skewed immune responses driven by key allergens (e.g., Der p 1, Der p 2, Der p 23), and the impacts of climate change on allergy prevalence. It also summarizes cutting-edge progress in allergen-specific immunotherapy (AIT) and highlights critical research targets for diagnosis and treatment. Additionally, the review showcases abinScience’s high-quality recombinant proteins and antibody tools tailored for HDMA research, providing essential resources for mechanistic studies and therapeutic development.

詳細を見る

A Comprehensive Guide to Idiopathic Inflammatory Myopathies (IIM) | Review of Classification, Immune Mechanisms, and Therapeutic Frontiers

Idiopathic Inflammatory Myopathies (IIM) are a group of autoimmune disorders characterized by chronic myositis and multi-system involvement. This article systematically reviews the modern classification of IIM, subtype-specific immune mechanisms, key autoantibodies and their clinical significance, discusses core signaling pathways and therapeutic targets, and concludes with prospects for personalized treatment based on molecular subtyping and future research directions.

詳細を見る

2026 Nipah Virus Outbreak Update: Pathogenic Mechanisms, Research Advances, and Comprehensive Review of abinScience Tools

A new Nipah virus (NiV) outbreak hit West Bengal, India, in January 2026, with 5 confirmed cases (including healthcare workers) confirming nosocomial transmission and triggering global alerts. NiV, a Henipavirus with 40%-75% mortality and 4-45-day incubation, invades via G protein-Ephrin-B2/B3 binding and escapes immunity through P protein, causing severe encephalitis and respiratory distress.

詳細を見る

Marburg Virus 2026: Outbreak Updates, Virulence Mechanisms & Research Toolkit

Marburg virus disease is a high-consequence viral hemorrhagic fever with outbreak potential. This article reviews the 2025 Ethiopia outbreak context and highlights 2026 research priorities across four core modules: entry/antigenicity (GP), immune evasion (VP35/VP24), assembly/budding (VP40), and diagnostics (NP). We link these targets to common workflows including pseudovirus neutralization, interferon signaling assays, virus-like particle platforms, and serology development. A curated set of abinScience recombinant proteins and antibodies is provided to support fast project start-up, assay standardization, and reproducible Marburg research.

詳細を見る

組換えタンパク質

抗体

アッセイキット

製品で参照

注目コンテンツ

abinScienceについて

ニュース

クイックアクセス

お問い合わせ